Seyedoshohadaei Fariba, Mohammadbeigi Robabeh, Tahmuri Atefe, Ghaderi Ebrahim
Department of Obstetrics & Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Iran University of Medical Sciences, Tehran, Iran.
J Obstet Gynaecol Res. 2016 Mar;42(3):286-90. doi: 10.1111/jog.12894. Epub 2015 Dec 22.
Ectopic pregnancy is a medical emergency. The classic treatment for this condition is surgery but early diagnosis allows for non-surgical treatment. In recent years, intramuscular methotrexate has been considered, due to easy administration, its less invasive nature and low complications, but there are arguments about its effects. The aim of this study was to evaluate tubal patency after treatment of ectopic pregnancy with methotrexate and related factors.
This cross-sectional study was conducted on 80 women with ectopic pregnancy who were admitted to Sanandaj Be'sat Hospital in 2014. Patients who had successful treatment for ectopic pregnancy with single or multiple doses of methotrexate 50 mL/m(2) were enrolled. Three to 6 months after treatment, the patients were evaluated for tubal patency by hysterosalpingography. Data were analyzed using spss, t-tests, χ(2) -test and logistic regression.
The tubal patency rate after treatment of ectopic pregnancy with methotrexate was 75% in hysterosalpingography. The average size of the ectopic pregnancy mass of women with open fallopian tubes was 22.5 ± 7.0 mm and for women with closed fallopian tubes it was 34.7 ± 10.0 mm (P = 0.0001). β-human chorionic gonadotropin levels were 642.1 ± 850.5 in women with open fallopian tubes and 3816.3 ± 4487.3 for women with closed fallopian tubes (P = 0.0001). There was no significant correlation statistically between tubal patency with a history of stillbirth and number of pregnancies (P > 0.5). There was a statistically significant relation between tubal patency and the number of births and also methotrexate dose (P < 0.05).
Treatment of ectopic pregnancy with methotrexate is effective for saving tubal patency. Levels of human chorionic gonadotrophin-β < 1745, the treatment regimen of methotrexate (single or multiple doses) and ectopic pregnancy mass size smaller than 33.5 mm are significant predictors of tubal patency.
异位妊娠是一种医疗急症。针对这种情况的经典治疗方法是手术,但早期诊断可实现非手术治疗。近年来,由于肌内注射甲氨蝶呤给药方便、侵入性较小且并发症少,其被纳入考虑范围,但对于其效果存在争议。本研究的目的是评估甲氨蝶呤治疗异位妊娠后的输卵管通畅情况及相关因素。
本横断面研究对2014年入住萨南达杰贝萨特医院的80例异位妊娠女性进行。纳入用单剂量或多剂量50 mL/m²甲氨蝶呤成功治疗异位妊娠的患者。治疗后3至6个月,通过子宫输卵管造影术评估患者的输卵管通畅情况。使用SPSS软件进行数据分析,采用t检验、χ²检验和逻辑回归分析。
子宫输卵管造影显示,甲氨蝶呤治疗异位妊娠后的输卵管通畅率为75%。输卵管通畅的女性异位妊娠包块平均大小为22.5±7.0毫米,输卵管堵塞的女性为34.7±10.0毫米(P = 0.0001)。输卵管通畅的女性β-人绒毛膜促性腺激素水平为642.1±850.5,输卵管堵塞的女性为3816.3±4487.3(P = 0.0001)。输卵管通畅与死产史及妊娠次数之间无统计学显著相关性(P>0.5)。输卵管通畅与分娩次数及甲氨蝶呤剂量之间存在统计学显著关系(P<0.05)。
甲氨蝶呤治疗异位妊娠对保留输卵管通畅有效。人绒毛膜促性腺激素-β水平<1745、甲氨蝶呤治疗方案(单剂量或多剂量)以及异位妊娠包块大小小于33.5毫米是输卵管通畅的重要预测指标。